A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Clinical trial NCT03863223 · UNKNOWN
Trial details
- NCT number
- NCT03863223
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-22
- Primary completion
- 2022-12-30
- Enrollment
- 590
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.